Understanding and predicting fatigue, cardiovascular (CV) decline, and events after breast cancer treatment (UPBEAT): A prospective cardio-oncology study. Background: The opioid dose for an individual ...
REDWOOD CITY, Calif., Aug. 23, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
Efficacy of sequencing of cytotoxic and endocrine therapies in veterans with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results